Infertility, Female Clinical Trial
Official title:
Non-inferiority Randomized Controlled Study on Kidney Tonifying and Blood Circulation Regulating Therapy (Bu Shen Tiao Xue) of Different Intervention Courses in Improving IVF-ET Pregnancy Outcomes in DOR Patients
Patients with diminished ovarian reserve (DOR) who undergo in vitro fertilization and embryo transfer (IVF-ET) are included as the research subjects. The effects of Traditional Chinese Medicine (TCM) for kidney tonifying and blood circulation regulating of different intervention courses on ovarian hyporesponsiveness, IVF-ET outcome and clinical compliance in DOR patients are studied by a non-inferiority randomized controlled trial. The purpose is to identify the breakthrough point and treatment timing of TCM treatment, explore the best treatment course of TCM, and optimize the TCM therapeutic regimen.
Status | Not yet recruiting |
Enrollment | 266 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 42 Years |
Eligibility | Inclusion Criteria: 1. Female, 20 years old = age = 42 years old; 2. The menstrual cycle is generally regular; 21 days < menstrual cycle < 35 days; 3. Those who meet the diagnostic criteria for DOR in Western medicine; 4. Those who meet the TCM differential criteria of kidney deficiency syndrome; 5. Those who are scheduled to undergo IVF-ET; 6. Those who voluntarily participate in this clinical trial and sign a written informed consent. Exclusion Criteria: 1. Those who have a history of two or more spontaneous abortions (excluding biochemical pregnancy abortion) or three or more previous transplantations without achieving clinical pregnancy; 2. Those who have premature ovarian failure or ovarian gonadotropin resistance syndrome; 3. Those who have untreated uterine malformation or abnormality: double uterus, septate uterus (complete or incomplete); 4. Those who have untreated unilateral or bilateral hydrosalpinx; 5. Those who have uncured endometrial diseases (such as endometritis, endometrial polyps, endometriosis), adenomyosis, intrauterine adhesions, etc., and those with uterine fibroids of more than 4 cm; 6. Those who have endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia, hyperandrogenism, hypothyroidism, abnormal adrenal function, etc., which affect ovulation; 7. Infertile patients with abnormal ovarian function caused by immunological factors, genetic factors or congenital physiological defects; 8. Those who have received pelvic radiotherapy; 9. Those who are known or suspected of having sex hormone-related malignant tumors; 10. Those who are allergic or intolerable to the medications involved in the study; 11. Those with contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormal liver and renal function, diabetes, hypertension, thyroid disease, symptomatic heart disease, moderate to severe anemia, history of malignant tumor or history of thromboembolism or thrombosis formation tendency, serious mental illness, acute infection of urogenital system, sexually transmitted disease, extremely bad habits such as drug use, exposure to teratogenic radiation, poison, drugs (such as prednisone and other hormones, epinephrine, antibiotics, antihypertensive drugs, cardiovascular and cerebrovascular drugs, antiviral drugs) and are still under the effect of the drugs; and those whose uterus is unable to perform the function of pregnancy or who are intolerant of pregnancy due to physical diseases during pregnancy; 12. Those who have taken other TCMs or proprietary Chinese medicines that can invigorate the kidney or affect the evaluation of drug efficacy in the past 30 days; 13. Other patients who are deemed unsuitable to participate in this study by the researchers; 14. Those who are participating in other clinical trials; 15. Those who do not agree to participate in this study or do not sign the informed consent form. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of oocytes retrieved | The number of oocytes retrieved by puncture under the guidance of vaginal ultrasound | up to 15 weeks from enrollment | |
Secondary | High-quality embryo rate (%) | Number of high-quality embryos / the total number of normal cleavage embryos × 100% | up to 15 weeks from enrollment | |
Secondary | Clinical pregnancy rate | Ultrasound monitoring is performed 30 days after embryo transfer | up to 15 weeks from enrollment | |
Secondary | Compliance with the treatment plan | The situation of continuous treatment of the research subjects is recorded; the compliance of the experimental group = the number of cases who receive continuous treatment for 2 months / the total number of patients in the experimental group; the compliance of the control group = the number of cases who receive continuous treatment for 3 months / the total number of patients in the control group | up to 15 weeks from enrollment | |
Secondary | Gonadotrophin (Gn) administration day | Record the total gonadotrophin (Gn) administration day | up to 15 weeks from enrollment | |
Secondary | Gn dosage | Record the average dose of Gn administration | up to 15 weeks from enrollment | |
Secondary | Levels of LH | Obtained by blood sampling | up to 15 weeks from enrollment | |
Secondary | Levels of E2 | Obtained by blood sampling | up to 15 weeks from enrollment | |
Secondary | Levels of P | Obtained by blood sampling | up to 15 weeks from enrollment | |
Secondary | Antral follicle count (AFC) | Changes of AFC before and after TCM intervention | up to 15 weeks from enrollment | |
Secondary | Levels of FSH | Obtained by blood sampling | up to 15 weeks from enrollment | |
Secondary | Levels of AMH | Obtained by blood sampling | up to 15 weeks from enrollment | |
Secondary | Health economics indicators | Average daily cost and total cost | up to 15 weeks from enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05969574 -
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
|
||
Recruiting |
NCT05358483 -
PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Completed |
NCT03177538 -
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
|
Phase 4 | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Completed |
NCT04052464 -
The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
|
||
Withdrawn |
NCT04753736 -
Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC
|
N/A | |
Completed |
NCT03349905 -
Deferred Versus Fresh Embryo Transfers
|
N/A | |
Completed |
NCT05076981 -
Progesterone Levels During Ovulation and Luteal Phase
|
||
Completed |
NCT04096027 -
Cabergoline Before or After Oocyte Collection for Follicular Resolution
|
Phase 4 | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Terminated |
NCT01933633 -
Improved Fertility After Exercise in Overweight/Obese Women
|
N/A | |
Completed |
NCT01202656 -
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
|
Phase 1/Phase 2 | |
Terminated |
NCT01202643 -
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
|
Phase 1/Phase 2 | |
Completed |
NCT01408615 -
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
|
||
Enrolling by invitation |
NCT05698550 -
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
|
Phase 3 | |
Not yet recruiting |
NCT03910582 -
Personalized FET in RIF Patients With Displaced Dating
|
N/A | |
Completed |
NCT05440019 -
Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
|
||
Completed |
NCT05130125 -
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
|